Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 12/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30870368 | 1.00 | ALDH1A1 (0.45) | ALDH1A1DRD2CALCRLCHRM1LMNA | |
| SCHEMBL27207701 | 0.89 | ALDH1A1 (0.44) | ALDH1A1DRD2CALCRLCHRM1LMNA | |
| SCHEMBL22869588 | 0.86 | ALDH1A1 (0.47) | ALDH1A1DRD2CALCRLCHRM1LMNA | |
| SCHEMBL30870232 | 0.86 | ALDH1A1 (0.47) | ALDH1A1DRD2CALCRLCHRM1LMNA | |
| SCHEMBL22869395 | 0.86 | ALDH1A1 (0.47) | ALDH1A1DRD2CALCRLCHRM1LMNA | |
| SCHEMBL30870214 | 0.86 | ALDH1A1 (0.47) | ALDH1A1DRD2CALCRLCHRM1LMNA | |
| SCHEMBL22869851 | 0.85 | ALDH1A1 (0.46) | ALDH1A1DRD2CALCRLCHRM1LMNA | |
| SCHEMBL30870299 | 0.85 | ALDH1A1 (0.46) | ALDH1A1DRD2CALCRLCHRM1LMNA | |
| SCHEMBL22869702 | 0.85 | ALDH1A1 (0.46) | ALDH1A1DRD2CALCRLCHRM1LMNA | |
| SCHEMBL30870351 | 0.85 | ALDH1A1 (0.46) | ALDH1A1DRD2CALCRLCHRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112074511-B | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-04-26 | — | — | CN | claimed |
| CN-112074511-B | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-04-26 | — | — | CN | disclosed |
| US-20210002250-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002250-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP4X1, CYP11B2 | ALDH1A1 330/4885DRD2 1388/4885CALCRL 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.